---
layout: default
title: publications
---

<table style="background-color:#EEEEEE; border:0px solid black; border-collapse: collapse; padding: 5px 20px 5px 20px;">
  <tr>
    <th style="padding: 5px 20px 5px 20px;"><a href="index">Home</a></th>
    <th style="padding: 5px 20px 5px 20px;"><a href="publications">Publications</a></th>
    <th style="padding: 5px 20px 5px 20px;"><a href="projects">Projects</a></th>
    <th style="padding: 5px 20px 5px 20px;"><a href="software">Software</a></th>
    <th style="width:100%"></th>
  </tr>
</table>

## Publications

- <a href="https://doi.org/10.1002/hep.32427"><img src="https://img.shields.io/badge/DOI-10.1002/hep.32427-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. (2022)](https://doi.org/10.1002/hep.32427)**

- <a href="https://doi.org/10.3390/cancers12061433"><img src="https://img.shields.io/badge/DOI-10.3390/cancers12061433-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. (2020)](https://doi.org/10.3390/cancers12061433)**

- <a href="https://doi.org/10.1053/j.gastro.2020.05.056"><img src="https://img.shields.io/badge/DOI-10.1053/j.gastro.2020.05.056-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. (2020)](https://doi.org/10.1053/j.gastro.2020.05.056)**

- <a href="https://doi.org/10.1007/s11033-020-05245-5"><img src="https://img.shields.io/badge/DOI-10.1007/s11033--020--05245--5-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. (2020)](https://doi.org/10.1007/s11033-020-05245-5)**

- <a href="https://doi.org/10.1007/s10815-019-01670-z"><img src="https://img.shields.io/badge/DOI-10.1007/s10815--019--01670--z-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[The lipidome of endometrial fluid differs between implantative and non-implantative IVF cycles. (2020)](https://doi.org/10.1007/s10815-019-01670-z)**

- <a href="https://doi.org/10.5604/01.3001.0012.7906"><img src="https://img.shields.io/badge/DOI-10.5604/01.3001.0012.7906-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. (2019)](https://doi.org/10.5604/01.3001.0012.7906)**

- <a href="https://doi.org/10.14309/ctg.0000000000000003"><img src="https://img.shields.io/badge/DOI-10.14309/ctg.0000000000000003-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. (2019)](https://doi.org/10.14309/ctg.0000000000000003)**

- <a href="https://doi.org/10.1111/liv.14042"><img src="https://img.shields.io/badge/DOI-10.1111/liv.14042-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. (2019)](https://doi.org/10.1111/liv.14042)**

- <a href="https://doi.org/10.1111/liv.14042"><img src="https://img.shields.io/badge/DOI-10.1111/liv.14042-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. (2019)](https://doi.org/10.1111/liv.14042)**

- <a href="https://doi.org/10.1002/hep.30319"><img src="https://img.shields.io/badge/DOI-10.1002/hep.30319-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. (2019)](https://doi.org/10.1002/hep.30319)**

- <a href="https://doi.org/10.1002/hep4.1270"><img src="https://img.shields.io/badge/DOI-10.1002/hep4.1270-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. (2018)](https://doi.org/110.1002/hep4.1270)**

- <a href="https://doi.org/10.3390/cancers10090300"><img src="https://img.shields.io/badge/DOI-10.3390/cancers10090300-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. (2018)](https://doi.org/10.3390/cancers10090300)**

- <a href="https://doi.org/10.1002/hep4.1188"><img src="https://img.shields.io/badge/DOI-10.1002/hep4.1188-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. (2018)](https://doi.org/10.1002/hep4.1188)**

- <a href="https://doi.org/10.1111/dom.13285"><img src="https://img.shields.io/badge/DOI-10.1111/dom.13285-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. (2018)](https://doi.org/10.1111/dom.13285)**

- <a href="https://doi.org/10.1002/hep4.1107"><img src="https://img.shields.io/badge/DOI-10.1002/hep4.1107-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Role of Aramchol in steatohepatitis and fibrosis in mice. (2017)](https://doi.org/10.1002/hep4.1107)**

- <a href="https://doi.org/10.1038/s41598-017-10807-y"><img src="https://img.shields.io/badge/DOI-10.1038/s41598--017--10807--y-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. (2017)](https://doi.org/10.1038/s41598-017-10807-y)**

- <a href="https://doi.org/10.1053/j.gastro.2017.01.015"><img src="https://img.shields.io/badge/DOI-10.1053/j.gastro.2017.01.015-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. (2017)](https://doi.org/10.1053/j.gastro.2017.01.015)**

- <a href="https://doi.org/10.1016/j.dib.2015.02.008"><img src="https://img.shields.io/badge/DOI-10.1016/j.dib.2015.02.008-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Data in support of enhancing metabolomics research through data mining. (2015)](https://doi.org/10.1016/j.dib.2015.02.008)**

- <a href="https://doi.org/10.1016/j.jprot.2015.01.019"><img src="https://img.shields.io/badge/DOI-10.1016/j.jprot.2015.01.019-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Enhancing metabolomics research through data mining. (2015)](https://doi.org/10.1016/j.jprot.2015.01.019)**

- <a href="https://doi.org/10.1002/hep.26399"><img src="https://img.shields.io/badge/DOI-10.1002/hep.26399-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. (2013)](https://doi.org/10.1002/hep.26399)**

- <a href="https://doi.org/10.1002/hep.26052"><img src="https://img.shields.io/badge/DOI-10.1002/hep.26052-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease. (2013)](https://doi.org/10.1002/hep.26052)**

- <a href="https://doi.org/10.1021/pr201223p"><img src="https://img.shields.io/badge/DOI-10.1021/pr201223p-cfd8dc?labelColor=black&style=flat-square" align="right"/></a> **[Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression. (2012)](https://doi.org/10.1021/pr201223p)**
 

[back](./)
